Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Plus Platinum-based Chemotherapy in Advanced LCNEC
NCT05262985Phase 2Unknown
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in large cell neuroendocrine carcinoma of the lung (LCNEC). Status: unknown.
02
Drugs
durvalumab
03
Conditions
large cell neuroendocrine carcinoma of the lung (LCNEC)
Beyond the preview
Go deeper on NCT05262985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262985.